Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 8/20 | 0.53 |
| ▸ | PLG | P00747 | 4/20 | 0.52 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.44 |
| ▸ | HPN | P05981 | 1/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455404 | 1.00 | AVPR1B (0.53) | AVPR1BPLGAVPR1AHPNST14 | |
| SCHEMBL6461926 | 0.92 | PLG (0.54) | AVPR1BPLGAVPR1AF10PLAU | |
| SCHEMBL6461917 | 0.92 | PLG (0.54) | AVPR1BPLGAVPR1AF10PLAU | |
| SCHEMBL14959645 | 0.87 | PLG (0.52) | AVPR1BPLGAVPR1AST14PLAU | |
| SCHEMBL9196889 | 0.85 | PLG (0.59) | AVPR1BPLGAVPR1AF10PLAU | |
| SCHEMBL7315979 | 0.85 | PLG (0.59) | AVPR1BPLGAVPR1AF10PLAU | |
| SCHEMBL30116337 | 0.85 | PLG (0.59) | AVPR1BPLGAVPR1AF10PLAU | |
| Hydrochloric Acid SCHEMBL6461959 | 0.85 | PLG (0.59) | AVPR1BPLGAVPR1AF10PLAU | |
| SCHEMBL8267900 | 0.81 | PLG (0.60) | AVPR1BPLGAVPR1AF10PLAU | |
| SCHEMBL19139866 | 0.80 | PLG (0.50) | AVPR1BPLGAVPR1AF10PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875755-B2 | Antithrombotic compound | AKZO NOBEL N.V. (NL) | 2005-04-05 | — | — | US | disclosed |
| US-20030114361-A1 | Antithrombotic compound | MERCK SHARP & DOHME B.V. (NL) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114361-A1 | Antithrombotic compound | SERPINC1, ADAMTS13, F2 | AVPR1B 2066/4885PLG 44/4885AVPR1A 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.